Extramedullary plasmacytoma of the breast is rare. It is important to recognize the imaging findings and include it as a differential consideration in multiple myeloma patients with a breast mass. A 74-year-old woman undergoing chemotherapy for relapsed multiple myeloma presented with a palpable mass in her right breast. A screening mammogram four months prior was unremarkable. She underwent a diagnostic right mammogram which showed two well-circumscribed hyperdense masses. An ultrasound of the right breast showed mixed echogenic masses with indistinct margins and increased vascularity. Ultrasound guided biopsy confirmed the presence of an extramedullary plasmacytoma. A follow-up whole body PET/CT demonstrated an FDG-avid right breast mass with extensive osseous metastases.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943045 | PMC |
http://dx.doi.org/10.3941/jrcr.v14i12.4110 | DOI Listing |
Int J Surg Case Rep
December 2024
Department of Pathology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. Electronic address:
Introduction And Importance: Solitary extramedullary plasmacytoma (SEP) is a rare plasma cell neoplasm, constituting around 3 % of plasma cell malignancies. SEP typically presents as a single tumor, either in bone or soft tissue, without systemic disease, and is often misdiagnosed due to its nonspecific symptoms. Diagnosis requires biopsy and extensive imaging studies to exclude multiple myeloma and other malignancies.
View Article and Find Full Text PDFBlood Cancer J
December 2024
Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Multiple myeloma (MM) remains incurable despite novel therapeutics. A major contributor to the development of relapsed/refractory and resistant MM is extraosseous extramedullary disease (EMD), whose molecular biology is still not fully understood. We analyzed 528 MM patients who presented to our institution between 2014 and 2021 and who had undergone molecular testing.
View Article and Find Full Text PDFDigit J Ophthalmol
December 2024
Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India.
We report the case of a 60-year-old man diagnosed with unilateral, solitary, extramedullary plasmacytoma located in the right lacrimal sac fossa, with no systemic involvement. This rare plasma cell dyscrasia is usually found in the respiratory tract. Clinical and radiological features of the mass and histopathological results are described.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
Department of Respiratory and Critical Care Medicine, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province, China.
Rationale: Extramedullary plasmacytoma is an extremely rare malignant clonal plasmacytoma, which can occur in any tissue or organ of the body other than bone marrow hematopoietic tissue. Lesions mostly occur in the head and neck or upper respiratory tract, and rarely in the lower respiratory tract. Primary plasmacytoma of the lung, also known as primary pulmonary plasmacytoma (PPP), is rarer and is mainly diagnosed on the basis of the histopathology of biopsy tissue.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Radiological Diagnostics Center, The National Institute of Medicine of the Ministry of Interior and Administration, 02-507 Warsaw, Poland.
Multiple myeloma (MM) is the second most prevalent hematologic malignancy, particularly affecting the elderly. The disease often begins with a premalignant phase known as monoclonal gammopathy of undetermined significance (MGUS), solitary plasmacytoma (SP) and smoldering multiple myeloma (SMM). Multiple imaging modalities are employed throughout the disease continuum to assess bone lesions, prevent complications, detect intra- and extramedullary disease, and evaluate the risk of neurological complications.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!